Seminars in Hematology

Papers
(The TQCC of Seminars in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
CAR T-cell therapy comes of age: Introductory editorial for the special issue61
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial59
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies54
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation48
Clinical applications of circulating tumor DNA in Hodgkin lymphoma46
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia45
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?44
How to set up a clinical research center in Brazil, as an example of a middle-income country42
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-1939
Epidemiology and etiology of diffuse large B-cell lymphoma37
Somatic mutations in “benign” blood diseases30
Lessons learned from the Eµ-TCL1 mouse model of CLL27
The role of viruses in HIV-associated lymphomas26
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence22
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services20
Antibody and immunotherapy in diffuse large B-cell lymphoma20
TET2 mutation as prototypic clonal hematopoiesis lesion19
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future18
Vaccinations in patients with chronic lymphocytic leukemia17
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors17
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?16
The molecular map of CLL and Richter's syndrome16
outside front cover, PMS 8883 metallic AND 4/C15
outside front cover, PMS 8883 metallic AND 4/C14
Tribute to an editor: Neal S. Young As a Medical Editor and Writer14
Cellular and immunotherapies for myelodysplastic syndromes13
Clonal hematopoiesis13
outside front cover, PMS 8883 metallic AND 4/C12
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients12
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics12
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations11
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia10
The biology of classical Hodgkin lymphoma10
Aplastic anemia: Quo vadis?10
Challenges and opportunities of CAR T-cell therapies for CLL10
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead9
The pediatric approach to Hodgkin lymphoma8
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS8
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)8
Genetics of somatic auto-inflammatory disorders7
Understanding MDS stem cells: Advances and limitations7
VEXAS within the spectrum of rheumatologic disease7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials7
Somatic mutations in acquired pure red cell aplasia7
Somatic compensation of inherited bone marrow failure7
0.028683185577393